Literature DB >> 6886479

Antibody response to pneumococcal vaccination in children younger than five years of age.

R M Douglas, J C Paton, S J Duncan, D J Hansman.   

Abstract

Sera were analyzed by radioimmunoassay for type-specific pneumococcal antibody in 249 children aged six to 54 months, who were participating in a controlled trial of a 14-valent pneumococcal vaccine. Levels of serum antibody to all serotypes increased after immunization in all age groups tested. For all serotypes, the antibody response increased progressively with age whether response was viewed as antibody doubling, relative increase in geometric mean, or final antibody level. Responses were poor up to the age of five years for the important pediatric serotypes 6A, 14, 19F, and 23F. Seventeen children under the age of two years at the time of primary immunization received booster doses of vaccine six months later. There was no significant increase in antibody to any serotype, and the geometric mean antibody levels fell for most types. Immune response to the pediatric serotypes was poor until the age of 4.5 years.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6886479     DOI: 10.1093/infdis/148.1.131

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  96 in total

1.  Comparative genetics of capsular polysaccharide biosynthesis in Streptococcus pneumoniae types belonging to serogroup 19.

Authors:  J K Morona; R Morona; J C Paton
Journal:  J Bacteriol       Date:  1999-09       Impact factor: 3.490

2.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system.

Authors:  L D Erickson; L A Vogel; M Cascalho; J Wong; M Wabl; B G Durell; R J Noelle
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

4.  Empyema thoracis: not time to put down the knife.

Authors:  D Spencer
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 5.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

6.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

7.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

10.  Nucleotide sequence analysis of genes essential for capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 19F.

Authors:  A Guidolin; J K Morona; R Morona; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.